deltatrials
Terminated PHASE1 INTERVENTIONAL 2-arm NCT02601378

A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.

A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma

Sponsor: Novartis Pharmaceuticals

Conditions Uveal Melanoma
Interventions LXS196 LXS196 and HDM201
Updated 22 times since 2017 Last updated: Sep 27, 2022 Started: Feb 1, 2016 Primary completion: Jan 7, 2022 Completion: Jan 7, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The combination part of the study was terminated early due to business reasons

Other terminated trials from Novartis Pharmaceuticals

See all terminations from Novartis Pharmaceuticals

Other Uveal Melanoma trials with similar outcome

Browse all Uveal Melanoma trials

This PHASE1 trial investigates Uveal Melanoma and is currently terminated or withdrawn. Novartis Pharmaceuticals leads this study, which shows 22 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Dec 2017 · 10 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~May 2019 · 8 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Nov 2019 · 4 months · monthly snapshot~Nov 2019 – ~Mar 2020 · 4 months · monthly snapshot~Mar 2020 – ~Sep 2020 · 6 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~Oct 2022 · 3 months · monthly snapshot~Oct 2022 – ~Jul 2024 · 21 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

22 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Oct 2022 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Jul 2022 — Oct 2022 [monthly]

    Terminated PHASE1

    Status: Completed → Terminated

  5. Apr 2022 — Jul 2022 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 17 earlier versions

  1. Sep 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE1

  2. May 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  3. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE1

    Status: Active Not Recruiting → Recruiting

  4. Mar 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE1

  5. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1

  6. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  7. Mar 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE1

  8. Nov 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE1

  9. Jul 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  10. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE1

  11. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE1

  12. Sep 2018 — May 2019 [monthly]

    Recruiting PHASE1

  13. Jul 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

  14. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1

  15. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  16. Feb 2017 — Dec 2017 [monthly]

    Recruiting PHASE1

  17. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Feb 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations